CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>*Reimbursement status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemoradiation treatment for stage III and IV locally advanced nasopharyngeal carcinoma in patients where CISplatin is contraindicated or not tolerated¹</td>
<td>C11</td>
<td>00419a</td>
<td>Hospital</td>
</tr>
</tbody>
</table>

¹If the reimbursement status is not defined, the indication has yet to be assessed through the formal HSE reimbursement process.

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient’s individual clinical circumstances.

CARBOplatin is administered once every 7 days concomitantly with radiotherapy for 6 cycles. This treatment is followed by adjuvant chemotherapy consisting of CARBOplatin at AUC 5 intravenously and 5-FU infusion at 1000 mg/m²/day by 96h infusion every 4 weeks for a total of three cycles, beginning 4 weeks after the end of radiation therapy.

CARBOplatin is only to be administered concurrently with radiotherapy. Treatment with CARBOplatin should be discontinued if radiotherapy is truncated.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent and Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOplatin</td>
<td>AUC 2</td>
<td>IV infusion</td>
<td>250ml glucose 5% over 60 min</td>
<td>1-6</td>
</tr>
</tbody>
</table>

CARBOplatin dose:
The dose in mg of CARBOplatin to be administered is calculated as follows:

Dose (mg) = target AUC (mg/ml x min) x (GFR ml/min +25)

- Measured GFR (e.g. nuclear renogram) is preferred whenever feasible
- Estimation of GFR (eGFR) can be done by using the Wright formula or using the Cockcroft and Gault formula to measure creatinine clearance.
- The GFR used to calculate the AUC dosing should not exceed 125ml/min.
- For obese and anorexic patients the formulae may not give accurate results and measured GFR is recommended. Where obesity or overweight is likely to lead to an overestimate of GFR and isotope GFR is not available the use of the adjusted ideal body weight for Cockroft and Gault may be considered.(2)
WRIGHT FORMULA

There are two versions of the formula depending on how serum creatinine values are obtained, by the kinetic Jaffe method or the enzymatic method. The formula can be further adapted if covariant creatine kinase (CK) values are available (not shown).

1. SCr measured using enzymatic assay.

\[
GFR (\text{ml/min}) = \frac{(6230 - 32.8 \times \text{Age}) \times \text{BSA} \times (1 - 0.23 \times \text{Sex})}{\text{SCr (\mu mol/min)}}
\]

2. SCr measured using Jaffe assay

\[
GFR (\text{ml/min}) = \frac{(6580 - 38.8 \times \text{Age}) \times \text{BSA} \times (1 - 0.168 \times \text{Sex})}{\text{SCr (\mu mol/min)}}
\]

Key: Sex = 1 if female, 0 if male; Age in years; BSA = DuBois BSA

COCKCROFT-GAULT FORMULA

\[
GFR (\text{ml/min}) = S \times (140 - \text{age in years}) \times \text{wt (kg)}
\]

\[
\text{serum creatinine (micromol/L)}
\]

\[
S = 1.04 \text{ for females and 1.23 for males}
\]

ELIGIBILITY:

- Indications as above
- ECOG status 0-2

EXCLUSIONS:

- Hypersensitivity to CARBOplatin or any of the excipients
- Lactation

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.
TESTS:

Baseline tests:
- FBC
- Renal and liver profile
- Audiology if clinically indicated

Regular tests:
- FBC, renal and liver profile before each cycle.

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant

Haematological:

Table 1: Dose modification of CARBOplatin in haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x 10⁹/L) (on day of chemotherapy)</th>
<th>Platelets (x 10⁹/L) (at any stage during cycle)</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1</td>
<td>≥100</td>
<td>100% Dose</td>
</tr>
<tr>
<td>0.5 - 0.99</td>
<td>50-99</td>
<td>Delay treatment until recovery</td>
</tr>
<tr>
<td>&lt;0.5</td>
<td>&lt;50</td>
<td>Delay treatment until recovery and consider reducing CARBOplatin by 25% for subsequent cycles</td>
</tr>
</tbody>
</table>

Febrile neutropenia

Renal and Hepatic Impairment:

Table 2: Dose modification of CARBOplatin in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOplatin</td>
<td>See note below*</td>
<td>No dose modification required</td>
</tr>
</tbody>
</table>

- Patients with creatinine clearance values of < 60ml/min are at greater risk to develop myelosuppression.
- In case of GFR ≤ 20ml/min CARBOplatin should not be administered at all.
- If Cockroft & Gault or Wright formula are used, the dose should be adjusted per cycle based on a serum creatinine obtained within 48 hrs of drug administration.
- If isotope GFR is used, the dose should remain the same provided the serum creatinine is ≤110% of its value at the time of the isotope measurement. If the serum creatinine is higher than this, consideration should be given to remeasuring the GFR or to recalculating using Cockroft & Gault or Wright formulae taking care this does result in a dose reduction.
SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Moderate (Refer to local policy).

PREMEDICATIONS: None usually required

OTHER SUPPORTIVE CARE: No specific recommendations.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Hypersensitivity**: Reactions to CARBOplatin may develop in patients who have been previously exposed to platinum therapy. However allergic reactions have been observed upon initial exposure to CARBOplatin.

- **Neurotoxicity and ototoxicity**: Neurological evaluation and an assessment of hearing should be performed on a regular basis, especially in patients receiving high dose CARBOplatin. Neurotoxicity, such as paraesthesia, decreased deep tendon reflexes, and ototoxicity are more likely seen in patients previously treated with CISplatin, other platinum treatments and other ototoxic agents. Frequency of neurologic toxicity is also increased in patients older.

DRUG INTERACTIONS:

- Avoid concurrent use of CARBOplatin with nephrotoxic drugs (e.g. aminoglycosides, furosemide, NSAIDS) due to additive nephrotoxicity. If necessary monitor renal function closely.

- Avoid concurrent use with ototoxic drugs (e.g. aminoglycosides, furosemide, NSAIDS). If necessary perform regular audiometric testing.

- Current drug interaction databases should be consulted for more information.

ATC CODE:

CARBOplatin - L01XA02

REFERENCES:


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>08/05/2017</td>
<td></td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>2</td>
<td>15/05/2019</td>
<td>Inclusion of unlicensed status.</td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Standardisation of treatment table.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Update of drug interactions</td>
<td></td>
</tr>
</tbody>
</table>

NCCP Regimen: Carboplatin (AUC 2) Plus RT

Published: 11/05/2017

Review: 16/05/2021

Version number: 2

Tumour Group: Head & Neck

NCCP Regimen Code: 00419

ISMO Contributor: Prof Maccon Keane

Page 4 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
This regimen is outside its licensed indication in Ireland. Patients should be informed of the unlicensed nature of this indication and consented to treatment in line with the hospital’s policy on the use of unlicensed medication and unlicensed or “off label” indications. Prescribers should be aware of their responsibility in communicating any relevant information to the patient and also in ensuring that the unlicensed or “off label” indication has been acknowledged by the hospital’s Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at:
http://www.hse.ie/eng/services/list/5/cancer/profinfomedonc/cdmp/